{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:11:40Z","timestamp":1782929500546,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/Aims<\/jats:title>\n                <jats:p>The increasing use of biologic therapies for moderate to severe inflammatory bowel disease (IBD) highlights the importance of optimal treatment sequencing, particularly after vedolizumab (VDZ) exposure. Studies comparing the effectiveness of ustekinumab (UST) and antitumor necrosis factor (anti-TNF) agents post-VDZ are limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study analyzed VDZ-experienced IBD patients treated with UST or anti-TNF (adalimumab and infliximab) from May 2019 to January 2024. We conducted a comparative analysis of the 52-week treatment persistence between UST and anti-TNF therapies, while also identifying independent predictors that influence 52-week persistence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 110 participants, with 40 diagnosed with ulcerative colitis (UC) and 70 with Crohn\u2019s disease (CD). Demographics were comparable across treatment groups. The primary discontinuation reason for VDZ was secondary non-response. Kaplan-Meier analysis revealed that UST demonstrated superior 52-week persistence in overall IBD, CD and UC patients, compared to anti-TNF. Cox regression analysis also showed UST\u2019s superiority in overall IBD (HR: 0.15, 95% CI: 0.05\u20130.45, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), CD (HR: 0.09, 95% CI: 0.01\u20130.68, <jats:italic>p<\/jats:italic>\u2009=\u20090.02), and UC (HR: 0.28, 95% CI: 0.08\u20130.996, <jats:italic>p<\/jats:italic>\u2009=\u20090.049). The independent predictors for 52-week treatment persistence are Crohn\u2019s disease (Odds Ratio: 7.151, 95% CI: 1.763\u201328.995, <jats:italic>p<\/jats:italic>\u2009=\u20090.006) and UST treatment (Odds Ratio: 7.912, 95% CI: 1.789\u201334.992, <jats:italic>p<\/jats:italic>\u2009=\u20090.006). Notably, UST required more frequent dosing adjustments than anti-TNF, although both treatments exhibited comparable safety profiles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>UST demonstrated superior 52-week treatment persistence in IBD patients previously treated with VDZ compared to anti-TNF agents, albeit with a need for more frequent dose adjustments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03577-1","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:13:49Z","timestamp":1735629229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Horng-Yih","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Wei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Tang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Bin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsun","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puo-Hsien","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"issue":"9573","key":"3577_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627\u201340.","journal-title":"Lancet"},{"issue":"5","key":"3577_CR2","doi-asserted-by":"publisher","first-page":"e974","DOI":"10.1016\/j.cgh.2020.10.008","volume":"20","author":"G Khoudari","year":"2022","unstructured":"Khoudari G, Mansoor E, Click B, Alkhayyat M, Saleh MA, Sinh P, Katz J, Cooper GS, Regueiro M. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease patients after initiation of Biologics: a Cohort Study. Clin Gastroenterol Hepatol. 2022;20(5):e974\u201383.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"3577_CR3","first-page":"1225","volume":"26","author":"EL Barnes","year":"2020","unstructured":"Barnes EL, Jiang Y, Kappelman MD, Long MD, Sandler RS, Kinlaw AC, Herfarth HH. Decreasing Colectomy Rate for Ulcerative Colitis in the United States between 2007 and 2016: a Time Trend Analysis. Inflamm Bowel Dis. 2020;26(8):1225\u201331.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"3577_CR4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel Disease (STRIDE) Initiative of the International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"issue":"11","key":"3577_CR5","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","volume":"61","author":"MF Neurath","year":"2012","unstructured":"Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619\u201335.","journal-title":"Gut"},{"issue":"6","key":"3577_CR6","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1053\/j.gastro.2011.01.057","volume":"140","author":"TA Ullman","year":"2011","unstructured":"Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140(6):1807\u201316.","journal-title":"Gastroenterology"},{"issue":"8","key":"3577_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"3577_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, et al. ECCO Guidelines on therapeutics in Crohn\u2019s Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4\u201322.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"3577_CR9","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","volume":"158","author":"S Singh","year":"2020","unstructured":"Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the management of moderate to severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1465\u2013e14961417.","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"3577_CR10","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1\u2013106.","journal-title":"Gut"},{"issue":"5","key":"3577_CR11","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA Clinical Practice guidelines on the management of moderate to severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450\u201361.","journal-title":"Gastroenterology"},{"issue":"13","key":"3577_CR12","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr., Danese S, Colombel JF, T\u00f6r\u00fcner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, et al. Vedolizumab versus Adalimumab for Moderate-to-severe Ulcerative Colitis. N Engl J Med. 2019;381(13):1215\u201326.","journal-title":"N Engl J Med"},{"key":"3577_CR13","doi-asserted-by":"crossref","unstructured":"Albshesh A, Bannon L, Sharar Fischler T, Truyens M, Vavricka SR, Tepes K, Pugliese D, Savarino EV, Zittan E, Drobne D et al. Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn\u2019s Disease: A Multi-Center Retrospective Cohort Study. J Clin Med 2023, 12(7).","DOI":"10.3390\/jcm12072503"},{"issue":"11","key":"3577_CR14","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1093\/ibd\/izac269","volume":"29","author":"WC Lin","year":"2023","unstructured":"Lin WC, Tai WC, Chang CH, Tu CH, Feng IC, Shieh MJ, Chung CS, Yen HH, Chou JW, Wong JM, et al. Real-world evidence of effectiveness and safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: a prospective Nationwide Registry (VIOLET) study. Inflamm Bowel Dis. 2023;29(11):1730\u201340.","journal-title":"Inflamm Bowel Dis"},{"key":"3577_CR15","doi-asserted-by":"crossref","unstructured":"Elhag DA, Kumar M, Saadaoui M, Akobeng AK, Al-Mudahka F, Elawad M, Al Khodor S. Inflammatory bowel disease treatments and predictive biomarkers of therapeutic response. Int J Mol Sci 2022, 23(13).","DOI":"10.3390\/ijms23136966"},{"issue":"10","key":"3577_CR16","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1080\/00365521.2020.1803396","volume":"55","author":"S Vatn","year":"2020","unstructured":"Vatn S, Carstens A, Kristoffersen AB, Bergemalm D, Cas\u00e9n C, Moen AEF, Tannaes TM, Lindstr\u00f8m J, Detlie TE, Olbj\u00f8rn C, et al. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). Scand J Gastroenterol. 2020;55(10):1146\u201356.","journal-title":"Scand J Gastroenterol"},{"key":"3577_CR17","doi-asserted-by":"crossref","unstructured":"Raine T, Danese S. Breaking through the therapeutic ceiling: what will it take? Gastroenterology 2022;162(5):1507\u201311.","DOI":"10.1053\/j.gastro.2021.09.078"},{"issue":"10342","key":"3577_CR18","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200\u201311.","journal-title":"Lancet"},{"issue":"2","key":"3577_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3577_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","volume":"72","author":"B Barberio","year":"2023","unstructured":"Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis. Gut. 2023;72(2):264\u201374.","journal-title":"Gut"},{"issue":"3","key":"3577_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/apt.16436","volume":"54","author":"Y Ko","year":"2021","unstructured":"Ko Y, Paramsothy S, Yau Y, Leong RW. Superior treatment persistence with ustekinumab in Crohn\u2019s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the persistence Australian National IBD Cohort (PANIC) study. Aliment Pharmacol Ther. 2021;54(3):292\u2013301.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3577_CR22","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1186\/s12876-022-02583-5","volume":"22","author":"C Rayer","year":"2022","unstructured":"Rayer C, Nachury M, Bourreille A, Roblin X, Peyrin-Biroulet L, Viennot S, Flamant M, Laharie D, Caron B, Dewitte M, et al. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn\u2019s disease: a multicentre retrospective study. BMC Gastroenterol. 2022;22(1):498.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"3577_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","volume":"21","author":"T Straatmijer","year":"2023","unstructured":"Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven AA, Bodelier A, de Boer NKH, Dijkstra G, Festen N, et al. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis patients: a Nationwide Dutch Registry Study. Clin Gastroenterol Hepatol. 2023;21(1):182\u2013e191182.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3577_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12876-022-02225-w","volume":"22","author":"HK Hyun","year":"2022","unstructured":"Hyun HK, Zhang HS, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn\u2019s disease in patients with prior failure of anti-tumour necrosis factor treatment. BMC Gastroenterol. 2022;22(1):143.","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"3577_CR25","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.14309\/ajg.0000000000001773","volume":"117","author":"S Onali","year":"2022","unstructured":"Onali S, Pugliese D, Caprioli FA, Orlando A, Biancone L, Nardone OM, Imperatore N, Fiorino G, Cappello M, Viola A, et al. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn\u2019s Disease patients\u2019 failure to TNF-Alpha inhibitors. Am J Gastroenterol. 2022;117(8):1279\u201387.","journal-title":"Am J Gastroenterol"},{"key":"3577_CR26","doi-asserted-by":"crossref","unstructured":"Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JR. 1-Year comparison of clinical and endoscopic outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis after Anti-tumor Necrosis factor failure: a real-world cohort study in the United States. Inflamm Bowel Dis 2023.","DOI":"10.1093\/ibd\/izad165"},{"issue":"1","key":"3577_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/apt.15745","volume":"52","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Lowenberg M, de Boer NK, Oldenburg B, Srivastava N, Jansen JM, Bodelier AGL, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn\u2019s disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020;52(1):123\u201334.","journal-title":"Aliment Pharmacol Ther"},{"key":"3577_CR28","doi-asserted-by":"publisher","first-page":"175628482211443","DOI":"10.1177\/17562848221144349","volume":"15","author":"P Bacsur","year":"2022","unstructured":"Bacsur P, Matuz M, Resal T, Miheller P, Szamosi T, Schafer E, Sarlos P, Ilias A, Szanto K, Rutka M, et al. Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn\u2019s disease: results from a multicentre cohort study. Th Adv Gastroenterol. 2022;15:17562848221144349.","journal-title":"Th Adv Gastroenterol"},{"issue":"10","key":"3577_CR29","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/apt.15706","volume":"51","author":"H Alric","year":"2020","unstructured":"Alric H, Amiot A, Kirchgesner J, Treton X, Allez M, Bouhnik Y, Beaugerie L, Carbonnel F, Meyer A. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn\u2019s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51(10):948\u201357.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3577_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.dld.2022.06.029","volume":"55","author":"L Melotti","year":"2023","unstructured":"Melotti L, Dussias NK, Salice M, Calabrese C, Baldoni M, Scaioli E, Belluzzi A, Mazzotta E, Gionchetti P, Rizzello F. Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn\u2019s disease. Dig Liver Dis. 2023;55(2):230\u20134.","journal-title":"Dig Liver Dis"},{"key":"3577_CR31","doi-asserted-by":"publisher","first-page":"S382","DOI":"10.14309\/00000434-201810001-00681","volume":"113","author":"TE Ritter","year":"2018","unstructured":"Ritter TE, Fourment C, Okoro TC, Hardin TC, Van Anglen LJ. Failure of Vedolizumab as First-Line Biologic does not decrease response rates of second-line therapy: 681. Official J Am Coll Gastroenterol | ACG. 2018;113:S382\u20133.","journal-title":"Official J Am Coll Gastroenterol | ACG"},{"issue":"Supplement1","key":"3577_CR32","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1093\/ibd\/zaa010.180","volume":"26","author":"M Dolinger","year":"2020","unstructured":"Dolinger M, Rolfes P, Phan B, Pan S, Dubinsky M. P082 anti-TNF efficacy after primary vedolizumab failure in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(Supplement1):S71\u20132.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3577_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJMc1915042","volume":"382","author":"CR Rowan","year":"2020","unstructured":"Rowan CR, Boland K, Harewood GC. Ustekinumab as induction and maintenance therapy for Ulcerative Colitis. N Engl J Med. 2020;382(1):91.","journal-title":"N Engl J Med"},{"issue":"8","key":"3577_CR34","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjac030","volume":"16","author":"MT Abreu","year":"2022","unstructured":"Abreu MT, Rowbotham DS, Danese S, Sandborn WJ, Miao Y, Zhang H, Tikhonov I, Panaccione R, Hisamatsu T, Scherl EJ, et al. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis through 3 years: UNIFI Long-Term Extension. J Crohns Colitis. 2022;16(8):1222\u201334.","journal-title":"J Crohns Colitis"},{"issue":"20","key":"3577_CR35","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s Disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"issue":"1","key":"3577_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12876-022-02280-3","volume":"22","author":"RS Parra","year":"2022","unstructured":"Parra RS, Chebli JMF, Queiroz NSF, Dami\u00e3o A, de Azevedo MFC, Chebli LA, Bertges ER, Alves Junior AJT, Ambrogini Junior O, da Silva B, et al. Long-term effectiveness and safety of ustekinumab in bio-na\u00efve and bio-experienced anti-tumor necrosis factor patients with Crohn\u2019s disease: a real-world multicenter Brazilian study. BMC Gastroenterol. 2022;22(1):199.","journal-title":"BMC Gastroenterol"},{"issue":"13","key":"3577_CR37","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, et al. Ustekinumab as induction and maintenance therapy for Ulcerative Colitis. N Engl J Med. 2019;381(13):1201\u201314.","journal-title":"N Engl J Med"},{"issue":"1","key":"3577_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cgh.2020.02.035","volume":"19","author":"JE Ollech","year":"2021","unstructured":"Ollech JE, Normatov I, Peleg N, Wang J, Patel SA, Rai V, Yi Y, Singer J, Dalal SR, Sakuraba A, et al. Effectiveness of Ustekinumab Dose Escalation in patients with Crohn\u2019s Disease. Clin Gastroenterol Hepatol. 2021;19(1):104\u201310.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3577_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/apt.15784","volume":"52","author":"U Kopylov","year":"2020","unstructured":"Kopylov U, Hanzel J, Liefferinckx C, De Marco D, Imperatore N, Plevris N, Baston-Rey I, Harris RJ, Truyens M, Domislovic V, et al. Effectiveness of ustekinumab dose escalation in Crohn\u2019s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. Aliment Pharmacol Ther. 2020;52(1):135\u201342.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"3577_CR40","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/ibd\/izaa282","volume":"27","author":"RS Dalal","year":"2021","unstructured":"Dalal RS, Njie C, Marcus J, Gupta S, Allegretti JR. Predictors of Ustekinumab failure in Crohn\u2019s Disease after Dose Intensification. Inflamm Bowel Dis. 2021;27(8):1294\u2013301.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"3577_CR41","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1016\/j.cgh.2021.10.002","volume":"20","author":"J Meserve","year":"2022","unstructured":"Meserve J, Ma C, Dulai PS, Jairath V, Singh S. Effectiveness of Reinduction and\/or dose escalation of Ustekinumab in Crohn\u2019s Disease: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2728\u2013e27402721.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"3577_CR42","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/ibd\/izac164","volume":"29","author":"RS Dalal","year":"2023","unstructured":"Dalal RS, Pruce JC, Allegretti JR. Long-term outcomes after Ustekinumab Dose Intensification for Inflammatory Bowel diseases. Inflamm Bowel Dis. 2023;29(5):830\u20133.","journal-title":"Inflamm Bowel Dis"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03577-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03577-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03577-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T08:02:42Z","timestamp":1735632162000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03577-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3577"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03577-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"1 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board (IRB) of the Chang Gung Medical Foundation (approval document No. 202400030B0: \u201cDiagnosis, Treatment, and Prognosis of Inflammatory Bowel Disease\u201d). The IRB waived the requirement for signed informed consent from individual patients for reviewing medical records in the electronic medical record system as it was a retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was not funded by grants or other financial sponsors. The authors have no financial arrangements for the company whose products are discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosures"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"483"}}